Member Info for Timster

Is that the royal "we" sujood?

14 more sleeps

Bench to bedside

Interesting avacta started using that too:

Avacta Therapeutics’ ‘bench to bedside’ concept starts with a clear goal in mind: to better serve the unmet needs of cancer patients, and to radically improve treatment experiences and outcomes for all.

"AVA6000 as a first line treatment"

Ambiguous?

The RNS says so BV

the Company intends to begin a short study to explore more frequent dosing (fortnightly) of AVA6000 as a first line treatment in patients with soft tissue sarcoma. The study is expected to begin in Q4 2023 subject to receipt of approval of a protocol amendment from the US Food & Drug Administration (FDA).

The study is designed to determine whether fortnightly or three weekly dosing should be the recommended Phase 2 dosing regimen, as well as potentially providing additional indications of activity in soft tissue sarcoma patients. The study will replace the much longer planned Phase 1b efficacy study, and is expected to allow the Company to bring forward the start of the potentially pivotal Phase 2 efficacy study into 2024.

But it's still about safety and tolerability and not efficacy. But after seeing a significant reduction in an STS patient who is end of life already , then probability would say they would see efficacy.

If it's as good as we think it will silence the FUD crew and that's got to be a massive positive.

Fortnightly as a first line treatment for STS, there's some pretty big inflection points coming there and relatively quickly once it is started.

"I think Results from cohort 7, will trigger the application for the fortnightly trial."

Not what we've been told via RNS:

in parallel with the completion of cohort 7, the Company intends to begin a short study to explore more frequent dosing (fortnightly) of AVA6000 as a first line treatment in patients with soft tissue sarcoma. The study is expected to begin in Q4 2023 subject to receipt of approval of a protocol amendment from the US Food & Drug Administration (FDA).

Maybe brokers will increase the success case by 1 or 2 percent too.

To be fair I probably agree, the data RNS will I presume include a link to the full published data which only a few retail investors will understand.

The summary in the RNS will be what they have already told us

-pre|CISION works

- safety and tolerability profile is exceptional

-early efficacy has been observed.

If there are case studies of those who have seen significant tumour reduction then that will peak more interest surely.

What it will do though is provide unequivocal proof that what Avacta have been telling us is true.

It's a massive milestone in the clinical trial I reckon we'll see lft level share prices.

I'd agree with ice, licenses or take out is the real mover.

Bloody DERAMPER

No more an interesting open than any other Monday, unless there's an RNS.

Busy week ahead!

It's Friday Hurstbot, has your calendar module become corrupted?

So annoyed it's not Christmas day yet

Very true, the FDA may have already raised their concerns over the similarity to ribena in the substrate.....

Bell left due to wanting to use original ribena and Al insisted mango and lime.

The good news is size buyers will have to pay 145+ any minute.

From Bella's post yesterday on the approval process, one of the team:

Medical Officer: Reviews all clinical study information and data before, during, and after the trial is complete

I'd give it a 10-40% chance of success 😀

True, time to stop add to the filter list.

It's a dead cert when the data is released eggy will search and search it for what eggy can perceive has a negative then repeat it over and over again. Watch it unfold....